Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double Dummy Controlled, Parallel Group Study of the Efficacy and Safety of MabThera (Rituximab) Alone or in Combination With Either Cyclophosphamide or Methotrexate, in Patients With Rheumatoid Arthritis

NCT02693210 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02693210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02693210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double Dummy Controlled, Parallel Group Study of the Efficacy and Safety of MabThera (Rituximab) Alone or in Combination With Either Cyclophosphamide or Methotrexate, in Patients With Rheumatoid Arthritis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2001
Completion date
August 31, 2004
Enrollment
161 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis